Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancer
As there were no significant outcome differences in DFS or OS between the studied schedules of AC and P with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.
Authors
- Azka Ali (ORCID: https://orcid.org/0000-0001-7476-6664)
- Danika L. Lew
- Julie R. Gralow (ORCID: https://orcid.org/0000-0003-3837-9928)
- Lawrence E. Flaherty
- Kathy S. Albain (ORCID: https://orcid.org/0000-0002-2899-2473)
- Bradley A. McGregor (ORCID: https://orcid.org/0000-0002-8298-0289)
- Gordan Srkalović (ORCID: https://orcid.org/0000-0003-3519-0409)
- William E. Barlow (ORCID: https://orcid.org/0000-0003-4651-2282)
- Muhammad Salim (ORCID: https://orcid.org/0009-0009-7454-6018)
- G. Burton
- Helen K. Chew
- T. Hobday
- Lajos Pusztai
- George T Budd
- Claudine Isaacs
- Halle C F Moore
- Gabriel N Hortobagyi
- Priyanka Sharma
Institutions
- Sparrow Health System (US)
- American Society of Clinical Oncology (US)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Loyola University Chicago (US)
- Georgetown University Medical Center (US)
- Yale Cancer Center (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Saskatchewan Cancer Agency (CA)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- University of Kansas Medical Center (US)
- Mayo Clinic in Florida (US)
- University of California Davis Medical Center (US)
- Louisiana State University Health Sciences Center Shreveport (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1093/jncics/pkag024
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00